Treatment of primary CML cells with either EZH2 inhibitors or TKIs alone significantly upregulated H3K27me3 targets, and combined treatment with TKIs and EZH2 inhibitors significantly killed CML-LSCs, both in vitro and in bone marrow murine xenografts (34). The gene discussed is EZH2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.